Hansa Biopharma EBITDA vs. Book Value Per Share
| HNSBF Stock | USD 2.93 0.00 0.00% |
For Hansa Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Hansa Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Hansa Biopharma AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Hansa Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Hansa Biopharma AB over time as well as its relative position and ranking within its peers.
Hansa |
Hansa Biopharma AB Book Value Per Share vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Hansa Biopharma's current stock value. Our valuation model uses many indicators to compare Hansa Biopharma value to that of its competitors to determine the firm's financial worth. Hansa Biopharma AB is one of the top stocks in ebitda category among related companies. It is one of the top stocks in book value per share category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Hansa Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Hansa Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hansa Biopharma's earnings, one of the primary drivers of an investment's value.Hansa Book Value Per Share vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Hansa Biopharma |
| = | (538.83 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Hansa Biopharma |
| = | 1.50 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Hansa Book Value Per Share Comparison
Hansa Biopharma is currently under evaluation in book value per share category among related companies.
Hansa Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Hansa Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Hansa Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Hansa Biopharma's change in net profit over the period of time. It can combine multiple indicators of Hansa Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Hansa Biopharma AB , a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G -mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. Hansa Biopharma AB was incorporated in 2007 and is headquartered in Lund, Sweden. Hansa Medical is traded on OTC Exchange in the United States.
Hansa Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Hansa Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Hansa Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Hansa Biopharma's important profitability drivers and their relationship over time.
Use Hansa Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Hansa Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hansa Biopharma will appreciate offsetting losses from the drop in the long position's value.Hansa Biopharma Pair Trading
Hansa Biopharma AB Pair Trading Analysis
The ability to find closely correlated positions to Hansa Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hansa Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hansa Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hansa Biopharma AB to buy it.
The correlation of Hansa Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hansa Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hansa Biopharma AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hansa Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Hansa Biopharma position
In addition to having Hansa Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Value Funds Thematic Idea Now
Large Value Funds
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. Note that the Hansa Biopharma AB information on this page should be used as a complementary analysis to other Hansa Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Hansa Pink Sheet analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
To fully project Hansa Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Hansa Biopharma AB at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Hansa Biopharma's income statement, its balance sheet, and the statement of cash flows.